- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Virtual patient.
Displaying page 1 of 2.
EudraCT Number: 2005-001866-15 | Sponsor Protocol Number: 1182.71 | Start Date*: 2007-07-12 |
Sponsor Name:Boehringer Ingelheim France SAS | ||
Full Title: A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in three-clas... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GR (Completed) PT (Prematurely Ended) IT (Prematurely Ended) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003812-30 | Sponsor Protocol Number: NL70495.078.19 | Start Date*: 2020-10-21 |
Sponsor Name:Erasmus MC | ||
Full Title: Primovist CT: proof of concept | ||
Medical condition: Hepatocellular adenoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003940-21 | Sponsor Protocol Number: BILA-3918/PED | Start Date*: 2019-01-11 |
Sponsor Name:FAES FARMA, S.A. | ||
Full Title: A pilot, multicentre, single-blind, randomized, placebo-controlled, parallel-group clinical trial, to assess the safety of Bilastine treatment regarding psychomotor performance using a virtual real... | ||
Medical condition: Allergic rhinoconjunctivitis (both seasonal allergic rhinitis -SAR- and perennial allergic rhinitis -PAR-) and/or urticaria. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004586-41 | Sponsor Protocol Number: CHUBX2012/16 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Cognitive remediation in Attention Deficit Disorder with or without Hyperactivity (ADHD) children : Comparison between three therapeutic strategies : cognitive remediation with a virtual classroom ... | |||||||||||||
Medical condition: Attention Deficit Disorder with or without Hyperactivity | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000186-11 | Sponsor Protocol Number: Dresden-PPP-Trial | Start Date*: 2006-09-22 |
Sponsor Name:Med. Klinik / Kardiologie der Med. Fakultät Carl Gustav Carus an der Technischen Unversität Dresden | ||
Full Title: Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary... | ||
Medical condition: Male or female non-diabetic patients with coronary heart disease with AP or NSTEMI with indication for stent implantation and one additional coronary artery plaque (stenosis < 50%) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000319-21 | Sponsor Protocol Number: ClonDO | Start Date*: 2021-12-20 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial) | ||
Medical condition: Posttraumatic Stress Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001244-15 | Sponsor Protocol Number: D22-P006 | Start Date*: 2023-01-12 |
Sponsor Name:GHU Paris Psychiatrie et Neurosciences | ||
Full Title: Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial - PsyCARE_Trial | ||
Medical condition: early psychosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002640-70 | Sponsor Protocol Number: 20-HMedIdeS-19 | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Hansa Biopharma AB | |||||||||||||
Full Title: A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase tre... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004727-18 | Sponsor Protocol Number: CORUNO/II/05.1 | Start Date*: 2008-06-20 | |||||||||||
Sponsor Name:THERABEL PHARMACEUTICAL Ltd | |||||||||||||
Full Title: EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME. | |||||||||||||
Medical condition: Randomized, double-blind, placebo-controlled, add-on study in two parallel groups. Patients admitted for Non ST Segment Elevation Acute Coronary Syndromes will undergo a coronary angiography accord... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013074-41 | Sponsor Protocol Number: CRAD001ANO02 | Start Date*: 2009-11-10 | |||||||||||
Sponsor Name:Novartis Norge AS | |||||||||||||
Full Title: A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®)and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant re... | |||||||||||||
Medical condition: Heart transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003381-21 | Sponsor Protocol Number: RAFAEL | Start Date*: 2023-09-11 |
Sponsor Name:Psyon, s.r.o. | ||
Full Title: Regression of atherosclerosis induced by life changing experience with psilocybin | ||
Medical condition: Ischemic Heart Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002857-41 | Sponsor Protocol Number: BORTEJECT | Start Date*: 2013-07-11 |
Sponsor Name:Universitätsklinik für Innere Medizin III, Medizinische Universität Wien | ||
Full Title: Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study) | ||
Medical condition: Late antibody-mediated kidney allograft rejection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001604-30 | Sponsor Protocol Number: 1001 | Start Date*: 2017-12-11 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial | ||
Medical condition: Antibody-mediated rejection of a kidney transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000154-19 | Sponsor Protocol Number: UC-0105/1701 | Start Date*: 2017-07-19 |
Sponsor Name:UNICANCER | ||
Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer | ||
Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004299-69 | Sponsor Protocol Number: ARCHITECT | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:Fundación Hipercolesterolemia Familiar | |||||||||||||
Full Title: Low interventional, open and multicentric clinical trial to evaluate the effect of alirocumab on volume, architecture and composition of atheroma plaque in patients with familial hypercholesterole... | |||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003726-23 | Sponsor Protocol Number: 1346-0013 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) FI (Completed) CZ (Completed) BE (Completed) LT (Completed) PT (Completed) AT (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001603-32 | Sponsor Protocol Number: iOM-04318 | Start Date*: 2016-06-14 | |||||||||||||||||||||
Sponsor Name:iOMEDICO AG | |||||||||||||||||||||||
Full Title: An open-label, multi-center, sINGlE arm clinical study to evaluate treatment efficacy and quality of life in women with hormone-receptor-positive, HER2-negative loco-regionally recurrent or metast... | |||||||||||||||||||||||
Medical condition: The study population includes postmenopausal patients with advanced (locally recurrent, inoperable and/or metastatic), HR+, HER2- breast cancer. For peri-/premenopausal patients, endocrine therapy ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002028-41 | Sponsor Protocol Number: HPX-2011-003 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Oxford University Hospitals NHS Trust | |||||||||||||
Full Title: A study to determine regional lung function in patients with Non-small cell lung cancer (NSCLC) undegoing radiotherapy using hyperpolarised xenon gas MR imaging | |||||||||||||
Medical condition: Non-small cell lung cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003744-84 | Sponsor Protocol Number: 1346-0012 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) NL (Completed) FR (Completed) SK (Completed) ES (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
